What question did this study set out to answer?

To assess the long-term safety and efficacy of dazukibart in adults with moderate-to-severe dermatomyositis.

Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates dazukibart’s long-term safety and efficacy in adults with dermatomyositis, indicating positive outcomes.

To assess the long-term safety and efficacy of dazukibart in adults with moderate-to-severe dermatomyositis.
Combined analysis from two cohorts (skin-predominant and muscle-predominant) over 92 weeks.
Participants received dazukibart (600 mg) during a 52-week open-label extension study.
Primary endpoint: incidence of treatment-emergent adverse events from weeks 24 to 92.
Treatment-related TEAEs were mild (55%), moderate (38%), and severe (7%).
Median improvement in CDASI-A was −24.0 (SP), −9.0 (MP), and −23.5 (pooled).
Total Improvement Score improved significantly in muscle-predominant cohort at week 76.

Vleugels et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark